Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Clinical Therapeutics

Volumn 37, Issue 7, 2015, Pages 1402-1419.e5

  O'Gorman, John ^a   Russell, Heidy K ^b   Li, Jie ^a   Phillips, Glenn ^a   Kurukulasuriya, Nuwan C ^a   Viglietta, Vissia ^a  

^a BIOGEN   (United States)

^b PROMETRIKA LLC   (United States)

Author keywords

aspirin; delayed release dimethyl fumarate; flushing; gastrointestinal; multiple sclerosis; prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; BENZOCAINE; CALCIUM CARBONATE; CORTICOSTEROID; DIPHENHYDRAMINE; FUMARIC ACID DIMETHYL ESTER; IBUPROFEN; LOPERAMIDE; OMEPRAZOLE; ONDANSETRON; PARACETAMOL; PLACEBO; PROSTAGLANDIN D2; DELAYED RELEASE FORMULATION; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOATING; CLINICAL ASSESSMENT TOOL; CONSTIPATION; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; INCIDENCE; INDIGESTION; LOWER ABDOMINAL PAIN; MALE; MODIFIED ACUTE GASTROINTESTINAL SYMPTOM SCALE; MODIFIED FLUSHING SEVERITY SCALE; MODIFIED GLOBAL FLUSHING SEVERITY SCALE; MODIFIED OVERALL GASTROINTESTINAL SYMPTOM SCALE; NAUSEA; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; UNITED STATES; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ABDOMINAL PAIN; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CHEMICALLY INDUCED; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREVENTION AND CONTROL; THERAPEUTIC USE;

ABDOMINAL PAIN; ADULT; ASPIRIN; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DIARRHEA; DIMETHYL FUMARATE; FEMALE; FLUSHING; HEALTHY VOLUNTEERS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84937643524     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.03.028     Document Type: Article

References (22)

1. R. Gold, L. Kappos, D.L. Arnold, and et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
2. R.J. Fox, D.H. Miller, J.T. Phillips, and et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis N Engl J Med 367 2012 1087 1097 Erratum in: N Engl J Med. 2012; 1367:1673
3. Theodore Phillips J, Selmaj K, Gold R, et al. Clinical significance of gastrointestinal and flushing events in MS patients treated with delayed-release dimethyl fumarate. International Journal of MS Care, 2015, http://dx.doi.org/10.7224/1537-2073.2014-069 (in press).
4. S.I. Sheikh, I. Nestorov, H. Russell, and et al. Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers Clin Ther 35 2013 1582 1594 e1589
5. T.A. Jacobson A "hot" topic in dyslipidemia management - "how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention Mayo Clin Proc 85 2010 365 379
6. J.F. Paolini, Y.B. Mitchel, R. Reyes, and et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial Int J Clin Pract 62 2008 896 904
7. J.M. Norquist, D.J. Watson, Q. Yu, and et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing Curr Med Res Opin 23 2007 1549 1560
8. R. Schuligoi, R. Schmidt, G. Geisslinger, and et al. PGD2 metabolism in plasma: kinetics and relationship with bioactivity on DP1 and CRTH2 receptors Biochem Pharmacol 74 2007 107 117
9. J.A. Awad, J.D. Morrow, and L.J. Roberts Simplification of the mass spectrometric assay for the major urinary metabolite of prostaglandin D2 J Chromatogr 617 1993 124 128
10. G.L. Milne, S.C. Sanchez, E.S. Musiek, and J.D. Morrow Quantification of F2-isoprostanes as a biomarker of oxidative stress Nat Protoc 2 2007 221 226
11. ICH harmonized tripartite guideline: guideline for Good Clinical Practice. J Postgrad Med. 2001;47:45-50.
12. WMA. Declaration of Helsinki. June 1964.
13. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the Liver. Appleton-Century-Crofts: New York 1978.
14. Tecfidera™ USPI [package insert]. Cambridge, MA: Biogen Idec; 2013.
15. 2014/SmPC TPI. Tecfidera® Summary of Product Characteristics, 13 Feb 2014, Biogen Idec Inc. 2014.
16. S. Bent, A. Padula, and A.L. Avins Brief communication: better ways to question patients about adverse medical events: a randomized, controlled trial Ann Intern Med 144 2006 257 261
17. F.D. Sheftell, M. Feleppa, S.J. Tepper, and et al. Assessment of adverse events associated with triptans - methods of assessment influence the results Headache 44 2004 978 982
18. M.S. Mora, Y. Nestoriuc, and W. Rief Lessons learned from placebo groups in antidepressant trials Philos Trans R Soc Lond B Biol Sci 366 2011 1879 1888
19. J.T. Phillips, M. Hutchinson, R. Fox, and et al. Managing flushing and gastrointestinal events associated with delayed-release dimethyl fumarate: experiences of an international panel Multiple Sclerosis and Related Disorders 3 2014 513 519
20. T.M. Atkinson, Y. Li, C.W. Coffey, and et al. Reliability of adverse symptom event reporting by clinicians Qual Life Res 21 2012 1159 1164
21. S.V. Pakhomov, S.J. Jacobsen, C.G. Chute, and V.L. Roger Agreement between patient-reported symptoms and their documentation in the medical record Am J Manag Care 14 2008 530 539
22. L. Kappos, R. Gold, D.H. Miller, and et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study Lancet 372 2008 1463 1472